Diaverum expands core dialysis clinic network

NewsGuard 100/100 Score

Diaverum, one of the world's leading renal care service providers, added the 250th clinic to its growing clinic network throughout Europe, Latin America, Australia, and the Middle East.

In discussing the latest development, Dag Andersson, CEO and President of Diaverum, said: "It was only two years ago that we passed the 200 clinic mark with the acquisition of a clinic in Spain, and I am now very pleased to see that we are passing the 250 mark by acquiring two additional clinics in Chile. In line with our company strategy we have significantly strengthened our positions in some selective key markets we wanted to grow in, e.g. Germany, the UK, Poland and Turkey. At the same time we have entered three new markets, i.e. Chile, Romania and Saudi Arabia - markets in which we are convinced our high quality care will make a real positive difference to patients' lives, while at the same time representing great future growth prospects for us. We are now setting our aim for 300 clinics".

High quality and efficiency

The main focus for Diaverum is to provide the highest level of quality care, while at the same time running the clinics in a very safe and efficient way. Thus, significant efforts are devoted to integrate each new clinic through a 100-day and 1-year integration plan. During this process the company ensures that its high standards of medical quality and safety are fully implemented, while at the same time making all additional investments required to run the clinics in a safe and efficient way.

Holistic care

Diaverum is also accelerating its pace to become a more holistic renal care provider. "In addition to expanding our core dialysis clinic network in existing and new markets, we are broadening our service offerings in areas like Home Care, Transplant Services, Vascular Access, and Preventive Care in selective countries" states Mans Olsson, Head of Business Development. "We are now well positioned to continue expanding these services in parallel to continuing executing our M&A program".

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Scientists discover new genetic cause of inherited kidney disease